# MK-1026-001 (NCT03162536)

> A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)

No report yet. It can be ordered.

- Drugs tested: nemtabrutinib
- Indication: relapsed or refractory hematologic malignancies

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03162536
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
- Conditions: Lymphoma, B-Cell; Small Lymphocytic Lymphoma; Chronic Lymphocytic Leukemia; Waldenstrom Macroglobulinemia; Mantle Cell Lymphoma; Diffuse Large B Cell Lymphoma; Richter's Transformation; Follicular Lymphoma; Marginal Zone Lymphoma
- Interventions: Nemtabrutinib
- Enrollment: 190
- Primary outcome: Phase 1: Number of Participants Experiencing Dose Limiting Toxicity (DLT)
- Primary outcome: Phase 1: Number of Participants Who Experienced an Adverse Event (AE)
- Primary outcome: Phase 1: Number of Participants Who Discontinued Study Treatment Due to an AE
- Primary outcome: Phase 2: Expansion Cohorts A, B & C: Objective Response Rate (ORR) per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Criteria as Assessed by the Investigator
- Primary outcome: Phase 2: Expansion Cohorts A, B, C: ORR per Lugano Classification as Assessed by the Investigator

## Indexed commentary on MK-1026-001 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=mk-1026-001-nct03162536